Active Ingredient(s): Alpelisib
FDA Approved: * May 24, 2019
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Piqray Overview

Alpelisib, sold under the brand name Piqray (as Pivikto in emerging markets), is a medication sold by Novartis and used to treat certain types of breast cancer.[5] It is used together with fulvestrant.[5] It is taken by mouth.[5]it is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced ...

Read more Piqray Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Alpelisib

Recent Piqray Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 150mg, 200mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Piqray: (3 results)

Sorted by National Drug Code
  • 0078-0701 Piqray 200 mg Oral Tablet by Novartis Pharmaceuticals Corporation
  • 0078-0708 Piqray 150 mg Oral Tablet by Novartis Pharmaceuticals Corporation
  • 0078-0715 PiqrayPiqray Kit by Novartis Pharmaceuticals Corporation

Other drugs which contain Alpelisib or a similar ingredient: (1 result)